查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439554

用于癌症诊断的液体活检 - 全球市场考虑、竞争格局、市场预测 (2030)

Liquid Biopsy in Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

全球癌症诊断液体活检市场规模将于 2023 年达到 76.4 亿美元，到 2030 年将达到 192.4 亿美元，预计 2024-2030 年期间复合年增长率为 16.64%。 各种癌症盛行率上升、微创手术需求增加、精准医疗需求增加以及产品开发技术创新等因素预计将推动癌症诊断液体活检市场的发展。

癌症诊断液体切片的市场动态

用于癌症诊断的液体活检市场的主要驱动因素之一是，由于癌症发病率的增加，对用于癌症诊断的液体活检的需求不断增长。 根据国际癌症研究机构进行的 GLOBOCAN 研究，估计 2020 年全球报告了 1,930 万新癌症病例和约 1,000 万癌症死亡病例。 此外，根据上述资料，肺癌仍是2020年癌症死亡的第一大原因，估计死亡人数为180万人（18%），其次是大肠直肠癌（9.4%）和肝癌。（8.3%）、胃癌（ 7.7%）和女性乳癌（6.9%）。 考虑到世界各地新癌症患者数量不断增加，我们正在开发传统活检的替代方法，以加快癌症诊断过程，并使患者和医疗保健专业人员更顺利。人们越来越重视开发方法。 此外，液体活检在肺癌和乳癌等治疗管理中的应用预计将进一步推动产品需求。 因此，癌症患者数量的增加预计将导致对液体活检产品和服务的需求增加。 因此，所有上述因素预计将有助于癌症诊断液体活检市场的成长。

此外，导致癌症诊断液体活检需求扩大的另一个主要因素是精准医学在癌症治疗中日益重要。 "精准医疗" 的概念，即根据肿瘤的生物学行为制定个人化治疗方案，被认为是癌症治疗的新方法。 精准医学的临床应用广泛，包括筛检、诊断、预后预测、治疗反应/抗药性预测、復发和转移的早期检测以及癌症生物分层等。 液体活检由于能够提供原发性和转移性肿瘤的多个非侵入性全局快照，因此在个人化医疗方面具有巨大的前景。 针对患者健康状况的客製化治疗已获得医生的广泛接受和关注。 液体活检在为患者开发个人化治疗方面发挥着重要作用。 液体活检即时提供有关肿瘤概况的重要信息，并帮助确定后续治疗步骤。 液体活检的潜力得到了市场参与者的认可，这一领域的产品开发兴趣日益浓厚就证明了这一点。 例如，2022 年 9 月，德国公司 Molecular Health GmbH 与韩国新创公司 EONE-Diagnomics Genome Center (EDGC) 合作，帮助其医疗保健提供者客户确定癌症患者的个人化治疗方案。我使其成为可能。 因此，精准医学的日益重要性和液体活检的优势预计将有助于预测期内用于癌症诊断的液体活检市场的成长。

然而，由于技术限制和缺乏技术标准化而导致错误结果的风险可能会对癌症诊断液体活检市场的成长带来一定的挑战。

在用于癌症诊断的液体活检市场中，由于采取控制COVID-19传播的措施，收入有所下降。 COVID-19 爆发期间的主要措施之一是暂停许多选择性手术和门诊就诊。 这项措施减少了市场对液体活检产品和服务的需求，因为在封锁初期，世界各地的医疗保健系统指南暂时专注于管理 COVID-19 患者数量。

本报告研究和分析了全球癌症诊断液体活检市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

目录

第1章癌症诊断液体切片市场报告介绍

第2章癌症诊断液体切片市场概要

  • 调查范围
  • 市场概览
  • 竞争评估
  • 财务基准

第3章监理与专利分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第4章癌症诊断液体切片市场主要因素分析

  • 推动癌症诊断市场的因素
    • 各种癌症的发生率不断增加
    • 对微创手术的需求不断增加
    • 日益关注精准医疗
    • 产品开发中的技术创新
  • 癌症诊断市场的限制与挑战
    • 结果不正确的风险
    • 程序缺乏标准化
  • 癌症诊断的液体活检市场机会
    • 液体切片在临床实务的应用有限
    • 扩大新兴经济体的市场覆盖范围

第5章癌症诊断液体切片市场的波特五力分析

第6章COVID-19对癌症诊断液体切片市场的影响分析

第7章癌症诊断液体切片市场布局

  • 依类型
    • 产品
    • 服务
  • 依样本类型
    • 血
    • 尿液
    • 唾液
  • 依生物标记类型
    • CTC
    • ctDNA
    • cfDNA
    • 其他
  • 依癌症类型
    • 肺癌
    • 乳癌
    • 大肠癌
  • 按技术
    • 聚合□炼式反应
    • 次世代定序
  • 按最终用户
    • 医院
    • 诊断中心
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第8章癌症诊断液体切片市场的公司与产品概况

  • Myriad Genetics Inc
  • Exact Sciences Corporation
  • Biocartis
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc
  • Biocept Inc
  • Agilent Technologies Inc
  • MDx Health
  • Neogenomics Laboratories
  • F. Hoffman La Roche Ltd
  • Guardant Health
  • Bio-Techne
  • Illumina Inc
  • QIAGEN
  • Lucence Health Inc
  • Personal Genome Diagnostics Inc
  • SAGA Diagnostics
  • Agena Bioscience Inc
  • The Menarini Group
  • MiRXES Pte Ltd.

第9章KOL浏览量

第 10 章参考文献

第 10 章专案方法

第 12 章关于 DelveInsight

第 13 章免责声明与联络我们

Product Code: DIMDCL0380

Liquid Biopsy in Cancer Diagnostics Market By Type (Product Type [Instruments And Reagents & Kits] And Services), By Sample Type (Blood, Urine, And Saliva), By Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, And Others), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, And Others), By Technique (Polymerase Chain Reaction And Next Generation Sequencing), By End User (Hospitals, Diagnostic Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of cancers and growing popularity of precision medicine

Global liquid biopsy in cancer diagnostics market was valued at USD 7.64 billion in 2023, growing at a CAGR of 16.64% during the forecast period from 2024 to 2030 to reach USD 19.24 billion by 2030. Factors such as the rising incidence of various cancers, growing demand for minimally invasive procedures, increasing demand of precision medicine, technical innovation in product development among other factors are expected to drive the liquid biopsy in cancer diagnostics market.

Liquid Biopsy in Cancer Diagnostics Market Dynamics:

One of the key aspects driving the liquid biopsy in cancer diagnostics market is the growing demand for liquid biopsy in cancer diagnostics due to increase in the cancer incidence. As per the GLOBOCAN study conducted by the International Agency for Research on Cancer, in 2020, an estimated number of 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) and near about 10.0 million cancer deaths were reported globally. The above-mentioned source further stated that in 2020, lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Considering the increase in the number of new cancer cases all over the globe, there has been a growing emphasis on developing an alternative to conventional biopsies to facilitate the cancer diagnosis process and make it smoother for both patients and healthcare providers. Furthermore, the application of liquid biopsy in therapy management for cancers such as lung and breast is further expected to boost the product demand. Thus, the increasing patient population of cancers would, in turn, lead to an increase in demand for liquid biopsy products and services. Therefore, all the aforementioned factors are projected to contribute to the growth of liquid biopsy in the cancer diagnostics market.

Furthermore, another key contributor in the growing demand for liquid biopsy in cancer diagnostics is the increasing prominence of precision medicine in cancer care. The concept of "precision medicine" or individualizing the treatment plan according to the biological behavior of the tumor is considered a new approach in cancer management. The clinical applications of precision medicine are diverse encompassing screening, diagnosis, prognosis, prediction of treatment response and resistance, early detection of recurrence/metastasis, and biologic cancer stratification. Liquid biopsies hold great promise for personalized medicine due to their ability to provide multiple non-invasive global snapshots of the primary and metastatic tumors. The customization of treatment specific to the patient's health condition has gained widespread acceptance and attention from physicians. Liquid biopsy plays an important role in developing customized treatments for patients. It provides vital real-time information about the tumor profile and helps decide the subsequent steps in the treatment. The potential of liquid biopsy is also being realized by market players, which is evident by their growing interest in product development in this domain. For instance, in September 2022, German firm Molecular Health GmbH collaborated with a South Korean startup EONE-Diagnomics Genome Center (EDGC) to help its healthcare provider customers identify personalized treatment options for cancer patients. Therefore, the growing prominence of precision medicine and the advantages of liquid biopsy are expected to contribute to the growth of liquid biopsy in the cancer diagnostics market during the forecast period.

However, risk of false results due to procedural limitations and lack of standardization of procedures may be certain challenging aspects for the liquid biopsy in cancer diagnostics market growth.

The liquid biopsy in cancer diagnostics market witnessed a dip in the generated revenue due to the implementation of measures to curb the spread of the COVID-19 infection. One of the major steps during the COVID surge was the suspension of numerous elective procedures and outpatient visits which reduced the demand for liquid biopsy products and services in the market as the healthcare system guidelines across the globe temporarily focused all their efforts on the management of COVID-19 infection patient load during the initial lockdown period. As per the data provided by the Cancer Research UK, in the UK alone, for example, urgent lung cancer referrals fell by up to 75% during the first lockdown. This did not correlate to the decrease in cases, but that fewer people sought and obtained the diagnosis they urgently need. Unfortunately, these trends were prominent across countries around the globe. Nevertheless, the market for liquid biopsy in cancer diagnostics is on a period of recovery owing to devising of strategies to transform cancer care during the pandemic and approval of liquid biopsy products such as Exosomal liquid biopsy prostate test in March 2022 by the US Food and Drug Administration thereby presenting a future outlook for the liquid biopsy in cancer diagnostics market during the forecast period.

Liquid Biopsy in Cancer Diagnostics Market Segment Analysis:

Liquid Biopsy in Cancer Diagnostics Market by Type (Product Type [Instruments and Reagents & Kits] and Services), by Sample Type (Blood, Urine, and Saliva), by Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, and Others), by Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, and Others), by Technique (Polymerase Chain Reaction and Next Generation Sequencing), by End User (Hospitals, Diagnostic Centers, and Others), by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the liquid biopsy in cancer diagnostics market, the services category is accounted for 73% of market revenue share in 2020. This can be ascribed to various aspects of services catered by this category. Many companies are operating in the domain where they offer services pertaining to liquid biopsy ranging from sample collection to NGS analysis. One such example is an Australia-based company, BARD1 that offers a sample preparation platform called NETs Biomarker Capture Platform. This platform is a patented technology of the company to revolutionize the performance of liquid biopsy diagnostic assays.

Another such company catering to the services aspect of the liquid biopsy domain is Biodesix. The company offers a wide range of services from clinical aspects to clients from a research background. For instance, the company employs blood-based, multiple technologies approaches for diagnostic research to uncover novel insights about the tumor biology and patient's immune response to cancer for biopharmaceutical therapeutics in clinical development. Therefore, considering the wide application area of services aspect of the liquid biopsy domain, the service category is expected to account for a formidable market share in the liquid biopsy in the cancer diagnostics market.

North America is expected to dominate the overall Liquid Biopsy in Cancer Diagnostics Market:

Among all the regions, North America is expected to account for the significant market share in the liquid biopsy in cancer diagnostics market. North America is estimated to account for the dominant market share because of the increasing prevalence of cancers, increasing focus on oncology research, supportive government policies promoting liquid biopsy research and a conducive environment for product development and launches among other factors in the region.

Among all the North American countries, United States accounted for 87% of revenue share in the North America liquid biopsy in cancer diagnostics market in 2020. One of the key reasons for high uptake of liquid biopsy products and services in the country was the high prevalence of cancers. For instance, according to the data provided by the National Cancer institute (United States), till April 2022, bladder, breast, colon and rectal, endometrial and kidney cancer were some of the common cancer types in the country. Besides, the high prevalence of Cancer, United States is considered as one of the key countries that invests heavily in healthcare services as well as medical research. The US Food and Drug Administration also provides a supportive environment for new technologies to reach the market with the provision of "breakthrough device" designation to emerging technologies and products in the medical devices domain. For instance, in April 2022, the US FDA awarded the breakthrough device designation to Inviata Limited for their liquid biopsy product for minimal residue disease (MRD) test. The regulatory body also awarded the same designation to Bluestar Genomics' noninvasive pancreatic cancer detection test.

Additionally, cancer diagnosis and treatment can be extremely cost intensive for patients even after medical insurance. The coverage of liquid biopsy test in insurance and reimbursement programs offered by the US government further acts as a booster for their uptake by end users. For instance, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer is covered under CMS National Coverage Policy. Thus, all the above-stated factors are expected to drive the market for liquid biopsy in cancer diagnostics in the United States.

Moreover, the increasing prevalence of lifestyle disorders that present as major risk factors in cancer development. For instance, as per the data provided by the Global Obesity Observatory (2023), Mexico presents a national risk of obesity development on a scale of 10 to be 8. This represents that the majority of the population in Mexico either falls in the bracket of the obese population or is highly susceptible to being obese in the coming years. Many studies have established that excess body fat increases the risk for several cancers, including colorectal, postmenopausal breast, uterine, esophageal, kidney, and pancreatic cancers. Additionally, the increase in aging population in the country is also said to contribute to cancer incidence. According to the 2022 data published by the World Bank Group, approximately 9,822,231 population in Mexico were aged 65 years and above in 2020. Therefore, the increasing prevalence of risk factors such as obesity and aging that may play a crucial role in cancer development has also resulted in the country's increasing prevalence of various cancers. This has been a major driving factor for the growing demand for liquid biopsy products and services in Mexico.

Liquid Biopsy in Cancer Diagnostics Market Key Players:

Some of the key market players operating in the liquid biopsy in cancer diagnostics market includes Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd. and others.

Recent Developmental Activities in Liquid Biopsy In Cancer Diagnostics Market:

In October 2022, Sysmex Inostics developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML). This new test, AML-MRD-SEQ, adds to the portfolio of ultra-sensitive Plasma-Safe-SeqS technology NGS tests available through Sysmex Inostics' CLIA lab services in Baltimore, Maryland in the United States.

In June 2022, NeoGenomics completed its acquisition for Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England.

In January 2022, Exact Sciences Corporation acquired Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to developing a blood-based, multi-cancer screening test.

Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report Study

Market analysis for current liquid biopsy in cancer diagnostics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the liquid biopsy in cancer diagnostics market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the global liquid biopsy in cancer diagnostics market.

Various opportunities available for the other competitor in the liquid biopsy in cancer diagnostics market space.

What are the top performing segments in 2023? How these segments will perform in 2030.

Which is the top-performing regions and countries in the current liquid biopsy in cancer diagnostics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for liquid biopsy in cancer diagnostics market growth in the coming future?

Target Audience who can be benefited from this Liquid Biopsy in Cancer Diagnostics Market Report Study

Liquid Biopsy in Cancer Diagnostics products providers

Research organizations and consulting companies

Liquid Biopsy in Cancer Diagnostics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in liquid biopsy in cancer diagnostics

Various End-users who want to know more about the liquid biopsy in cancer diagnostics market and latest technological developments in the liquid biopsy in cancer diagnostics market.

Frequently Asked Questions for Liquid Biopsy in Cancer Diagnostics Market:

1. What is Liquid Biopsy?

A liquid biopsy is a test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy. It is most commonly applied to the collection of peripheral blood for analysis of cell-free circulating tumor deoxyribonucleic acids (DNA).

2. What is the market for Global Liquid Biopsy in Cancer Diagnostics?

Global liquid biopsy in cancer diagnostics market was valued at USD 7.64 billion in 2023, growing at a CAGR of 16.64% during the forecast period from 2024 to 2030 to reach USD 19.24 billion by 2030.

3. What are the drivers for Global Liquid Biopsy in Cancer Diagnostics Market?

Factors such as the rising incidence of various cancers, growing demand for minimally invasive procedures, increasing prominence of precision medicine, technical innovation in product development among other factors are expected to drive the liquid biopsy in cancer diagnostics market.

4. Who are the key players operating in Global Liquid Biopsy in Cancer Diagnostics Market?

Some of the key market players operating in the liquid biopsy in cancer diagnostics market includes Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd. and others.

5. Which region has the highest share in Liquid Biopsy in Cancer Diagnostics market?

North America is estimated to account for the dominant market share because of the increasing prevalence of cancers, increasing focus on oncology research, supportive government policies promoting liquid biopsy research and a conducive environment for product development and launches among other factors in the region.

Table of Contents

1.Liquid Biopsy in Cancer Diagnostics Market Report Introduction

2.Liquid Biopsy in Cancer Diagnostics Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Liquid Biopsy in Cancer Diagnostics Market Key Factor Analysis

  • 4.1 Liquid Biopsy in Cancer Diagnostics Market Drivers
    • 4.1.1 Rising Incidence of Various Cancers
    • 4.1.2 Growing Demand for Minimally Invasive Procedures
    • 4.1.3 Growing Prominence of Precision Medicine
    • 4.1.4 Technical Innovation in Product Development
  • 4.2 Liquid Biopsy in Cancer Diagnostics Market Restraints and Challenges
    • 4.2.1 Risk of False Results
    • 4.2.2 Lack of Standardization of Procedures
  • 4.3 Liquid Biopsy in Cancer Diagnostics Market Opportunities
    • 4.3.1 Limited Utilization of Liquid Biopsy in Clinical Settings
    • 4.3.2 Expanding Market Reach in Emerging Economies

5. Liquid Biopsy in Cancer Diagnostics Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Liquid Biopsy in Cancer Diagnostics Market

7. Liquid Biopsy in Cancer Diagnostics Market Layout

  • 7.1 By Type
    • 7.1.1 Products
      • 7.1.1.1 Reagents & Kits
      • 7.1.1.2 Instruments
    • 7.1.2 Services
  • 7.2 By Sample Type
    • 7.2.1 Blood
    • 7.2.2 Urine
    • 7.2.3 Saliva
  • 7.3 By Biomarker Type
    • 7.3.1 Circulating Tumor Cells (CTCs)
    • 7.3.2 Circulating Tumor DNA (ctDNA)
    • 7.3.3 Circulating Free DNA (cfDNA)
    • 7.3.4 Others
  • 7.4 By Cancer Type
    • 7.4.1 Lung Cancer
    • 7.4.2 Breast Cancer
    • 7.4.3 Colon Cancer
    • 7.4.4 Others
  • 7.5 By Technique
    • 7.5.1 Polymerase Chain Reaction
    • 7.5.2 Next Generation Sequencing
  • 7.6 By End User
    • 7.6.1 Hospitals
    • 7.6.2 Diagnostic Centers
    • 7.6.3 Others
  • 7.7 By Geography
    • 7.7.1 North America
      • 7.7.1.1 North America Liquid Biopsy in Cancer Diagnostics Market, by Country
      • 7.7.1.1.1 United States
      • 7.7.1.1.2 Canada
      • 7.7.1.1.3 Mexico
    • 7.7.2 Europe
      • 7.7.2.1 Europe Liquid Biopsy in Cancer Diagnostics Market, by Country
      • 7.7.2.1.1 France
      • 7.7.2.1.2 Germany
      • 7.7.2.1.3 United Kingdom
      • 7.7.2.1.4 Italy
      • 7.7.2.1.5 Spain
      • 7.7.2.1.6 Russia
      • 7.7.2.1.7 Rest of Europe
    • 7.7.3 Asia-Pacific
      • 7.7.3.1 Asia-Pacific Liquid Biopsy in Cancer Diagnostics Market, by Country
      • 7.7.3.1.1 China
      • 7.7.3.1.2 Japan
      • 7.7.3.1.3 India
      • 7.7.3.1.4 Australia
      • 7.7.3.1.5 South Korea
      • 7.7.3.1.6 Rest of Asia Pacific
    • 7.7.4 Rest of the World (RoW)
      • 7.7.4.1 RoW Liquid Biopsy in Cancer Diagnostics Market, by Region
      • 7.7.4.1.1 Middle East
      • 7.7.4.1.2 Africa
      • 7.7.4.1.3 South America

8. Liquid Biopsy in Cancer Diagnostics Market Company and Product Profiles

  • 8.1 Myriad Genetics Inc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5. Entropy
  • 8.2 Exact Sciences Corporation
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5. Entropy
  • 8.3 Biocartis
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5. Entropy
  • 8.4 Sysmex Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5. Entropy
  • 8.5 Thermo Fisher Scientific Inc
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5. Entropy
  • 8.6 Biocept Inc
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5. Entropy
  • 8.7 Agilent Technologies Inc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5. Entropy
  • 8.8 MDx Health
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5. Entropy
  • 8.9 Neogenomics Laboratories
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5. Entropy
  • 8.10 F. Hoffman La Roche Ltd
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5. Entropy
  • 8.11 Guardant Health
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5. Entropy
  • 8.12 Bio-Techne
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5. Entropy
  • 8.13 Illumina Inc
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5. Entropy
  • 8.14 QIAGEN
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5. Entropy
  • 8.15 Lucence Health Inc
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5. Entropy
  • 8.16 Personal Genome Diagnostics Inc
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5. Entropy
  • 8.17 SAGA Diagnostics
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5. Entropy
  • 8.18 Agena Bioscience Inc
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5. Entropy
  • 8.19 The Menarini Group
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5. Entropy
  • 8.20 MiRXES Pte Ltd.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Bibliography

10. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Liquid Biopsy in Cancer Diagnostics Market
  • Table 3 Liquid Biopsy in Cancer Diagnostics Market in Global (2021-2030)
  • Table 4 Liquid Biopsy in Cancer Diagnostics Market in Global by Type (2021-2030)
  • Table 5 Liquid Biopsy in Cancer Diagnostics Market in Global by Sample Type (2021-2030)
  • Table 6 Liquid Biopsy in Cancer Diagnostics Market in Global by Biomarker Type (2021-2030)
  • Table 7 Liquid Biopsy in Cancer Diagnostics Market in Global by Cancer Type (2021-2030)
  • Table 8 Liquid Biopsy in Cancer Diagnostics Market in Global by Technique (2021-2030)
  • Table 9 Liquid Biopsy in Cancer Diagnostics Market in Global by End User (2021-2030)
  • Table 10 Liquid Biopsy in Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Table 11 Liquid Biopsy in Cancer Diagnostics Market in North America (2021-2030)
  • Table 18 Liquid Biopsy in Cancer Diagnostics Market in the US (2021-2030)
  • Table 19 Liquid Biopsy in Cancer Diagnostics Market in Canada (2021-2030)
  • Table 20 Liquid Biopsy in Cancer Diagnostics Market in Mexico (2021-2030)
  • Table 21 Liquid Biopsy in Cancer Diagnostics Market in Europe (2021-2030)
  • Table 29 Liquid Biopsy in Cancer Diagnostics Market in France (2021-2030)
  • Table 30 Liquid Biopsy in Cancer Diagnostics Market in Germany (2021-2030)
  • Table 31 Liquid Biopsy in Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Table 32 Liquid Biopsy in Cancer Diagnostics Market in Italy (2021-2030)
  • Table 33 Liquid Biopsy in Cancer Diagnostics Market in Spain (2021-2030)
  • Table 34 Liquid Biopsy in Cancer Diagnostics Market in Russia (2021-2030)
  • Table 35 Liquid Biopsy in Cancer Diagnostics Market in Rest of Europe (2021-2030)
  • Table 36 Liquid Biopsy in Cancer Diagnostics Market in APAC (2021-2030)
  • Table 44 Liquid Biopsy in Cancer Diagnostics Market in China (2021-2030)
  • Table 45 Liquid Biopsy in Cancer Diagnostics Market in Japan (2021-2030)
  • Table 46 Liquid Biopsy in Cancer Diagnostics Market in India (2021-2030)
  • Table 47 Liquid Biopsy in Cancer Diagnostics Market in Australia (2021-2030)
  • Table 48 Liquid Biopsy in Cancer Diagnostics Market in South Korea (2021-2030)
  • Table 49 Liquid Biopsy in Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Table 50 Liquid Biopsy in Cancer Diagnostics Market in Rest of World (2021-2030)
  • Table 58 Liquid Biopsy in Cancer Diagnostics Market in Middle East (2021-2030)
  • Table 59 Liquid Biopsy in Cancer Diagnostics Market in Africa (2021-2030)
  • Table 60 Liquid Biopsy in Cancer Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Liquid Biopsy in Cancer Diagnostics Market
  • Figure 3 Liquid Biopsy in Cancer Diagnostics Market in Global (2021-2030)
  • Figure 4 Liquid Biopsy in Cancer Diagnostics Market in Global by Type (2021-2030)
  • Figure 5 Liquid Biopsy in Cancer Diagnostics Market in Global by Sample Type (2021-2030)
  • Figure 6 Liquid Biopsy in Cancer Diagnostics Market in Global by Biomarker Type (2021-2030)
  • Figure 7 Liquid Biopsy in Cancer Diagnostics Market in Global by Cancer Type (2021-2030)
  • Figure 8 Liquid Biopsy in Cancer Diagnostics Market in Global by Technique (2021-2030)
  • Figure 9 Liquid Biopsy in Cancer Diagnostics Market in Global by End User (2021-2030)
  • Figure 10 Liquid Biopsy in Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Figure 11 Liquid Biopsy in Cancer Diagnostics Market in North America (2021-2030)
  • Figure 18 Liquid Biopsy in Cancer Diagnostics Market in the US (2021-2030)
  • Figure 19 Liquid Biopsy in Cancer Diagnostics Market in Canada (2021-2030)
  • Figure 20 Liquid Biopsy in Cancer Diagnostics Market in Mexico (2021-2030)
  • Figure 21 Liquid Biopsy in Cancer Diagnostics Market in Europe (2021-2030)
  • Figure 29 Liquid Biopsy in Cancer Diagnostics Market in France (2021-2030)
  • Figure 30 Liquid Biopsy in Cancer Diagnostics Market in Germany (2021-2030)
  • Figure 31 Liquid Biopsy in Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 32 Liquid Biopsy in Cancer Diagnostics Market in Italy (2021-2030)
  • Figure 33 Liquid Biopsy in Cancer Diagnostics Market in Spain (2021-2030)
  • Figure 34 Liquid Biopsy in Cancer Diagnostics Market in Russia (2021-2030)
  • Figure 35 Liquid Biopsy in Cancer Diagnostics Market in Rest of Europe (2021-2030)
  • Figure 36 Liquid Biopsy in Cancer Diagnostics Market in APAC (2021-2030)
  • Figure 44 Liquid Biopsy in Cancer Diagnostics Market in China (2021-2030)
  • Figure 45 Liquid Biopsy in Cancer Diagnostics Market in Japan (2021-2030)
  • Figure 46 Liquid Biopsy in Cancer Diagnostics Market in India (2021-2030)
  • Figure 47 Liquid Biopsy in Cancer Diagnostics Market in Australia (2021-2030)
  • Figure 48 Liquid Biopsy in Cancer Diagnostics Market in South Korea (2021-2030)
  • Figure 49 Liquid Biopsy in Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 50 Liquid Biopsy in Cancer Diagnostics Market in Rest of World (2021-2030)
  • Figure 58 Liquid Biopsy in Cancer Diagnostics Market in Middle East (2021-2030)
  • Figure 59 Liquid Biopsy in Cancer Diagnostics Market in Africa (2021-2030)
  • Figure 60 Liquid Biopsy in Cancer Diagnostics Market in South America (2021-2030)
  • Figure 61 Market Drivers
  • Figure 62 Market Barriers
  • Figure 63 Marker Opportunities
  • Figure 64 PORTER'S Five Force Analysis